Sequential Dialysis for Viral Disease
COVID-19 and other viral infections
Key Facts
About Halberd
Halberd Corporation is an early-stage biotech developing a proprietary extracorporeal treatment platform targeting blood-borne and neurological diseases. Its lead technology, the Sequential Dialysis Technique, is designed to physically remove pathogens and harmful molecules from bodily fluids, initially targeting COVID-19 and other viruses, with ambitions in PTSD, traumatic brain injury (TBI), and cancer. The company is publicly traded on the OTC Pink market (HALB), appears to be pre-revenue and pre-clinical, and is advancing its research through academic collaborations, including with Arizona State University and Mississippi State University. Recent strategic moves include the acquisition of NeuroSense AI Corp., a behavioral intelligence platform intended to augment its neuroscience programs.
View full company profile